Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Assembly Biosciences (ASMB) over the last 14 years, with Dec 2024 value amounting to -$40.2 million.

  • Assembly Biosciences' Income towards Parent Company rose 4.34% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.2 million, marking a year-over-year increase of 4.03%. This contributed to the annual value of -$40.2 million for FY2024, which is 34.38% up from last year.
  • Per Assembly Biosciences' latest filing, its Income towards Parent Company stood at -$40.2 million for FY2024, which was up 34.38% from -$61.2 million recorded in FY2023.
  • Over the past 5 years, Assembly Biosciences' Income towards Parent Company peaked at -$40.2 million during FY2024, and registered a low of -$129.9 million during FY2021.
  • Moreover, its 3-year median value for Income towards Parent Company was -$61.2 million (2023), whereas its average is -$64.8 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 36.34% in 2020, then slumped by 108.93% in 2021.
  • Assembly Biosciences' Income towards Parent Company (Yearly) stood at -$62.2 million in 2020, then plummeted by 108.93% to -$129.9 million in 2021, then climbed by 28.31% to -$93.1 million in 2022, then spiked by 34.23% to -$61.2 million in 2023, then skyrocketed by 34.38% to -$40.2 million in 2024.